Heyholder
‹ Activism Filings

KOREA ARLICO PHARM CO.,LTD. Q3 revenue KRW 53.1 billion, operating loss of KRW 0.8 billion

KOREA ARLICO PHARM CO.,LTD.· Periodic Report

AI summary · Not investment advice

Alico Pharm sold KRW 53.1 billion worth in Q3 but lost KRW 0.8 billion from its main business, turning from profit to loss versus a year earlier.

Operating profit · 3 months

KRW -802.3 million

Key facts

Revenue (3 months)
KRW 53.1 billion
Net income (3 months)
KRW -1.1 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 52.2 billion
Revenue (year to date)
KRW 148.3 billion
Operating profit (prior-year 3 months)
KRW 4.0 million
Operating profit (year to date)
KRW -7.1 billion
Net income (prior-year 3 months)
KRW -553.8 million
Net income (year to date)
KRW -2.5 billion

Commentary

AI commentary · Not investment advice

What happened

Alico Pharm reported its separate-basis results for the third quarter of 2026. Sales for the latest 3 months were KRW 53.08 billion. That is 1.7% more than the same period a year earlier, and 13.3% more than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 802.3 million. A year earlier it was a profit of KRW 4.0 million, so it turned to a loss. Net income (final profit after taxes and other items) for the 3 months was a loss of KRW 1.14 billion. A year earlier it was a loss of KRW 553.8 million.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 148.26 billion. Operating profit was a loss of KRW 7.14 billion. Net income was a loss of KRW 2.45 billion.

Comments

No comments yet

Comments from shareholders will appear here.